Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teduglutide Effects on GI Function in SBS
NCT02099084Phase 4Completed
- Sponsor
- Mayo Clinic
- Start
- Jan 2014
- Primary completion
- Mar 2015
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in short bowel syndrome (SBS) comparing Teduglutide First with Placebo First (2 arms). Primary endpoints: Gastric Emptying Half-Time (T1/2) and Overall Gut Transit. Started Jan 2014; status: completed.
02
Drugs
teduglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NCT02099084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02099084.